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Abstract
The recent emergence and rapid spread of a novel swine-derived H1N1 influenza virus has resulted in the first influenza
pandemic of this century. Monovalent vaccines have undergone preclinical and clinical development prior to initiation of
mass immunization campaigns. We have carried out a series of immunogenicity and protection studies following active
immunization of mice, which indicate that a whole virus, nonadjuvanted vaccine is immunogenic at low doses and protects
against live virus challenge. The immunogenicity in this model was comparable to that of a whole virus H5N1 vaccine, which
had previously been demonstrated to induce high levels of seroprotection in clinical studies. The efficacy of the H1N1
pandemic vaccine in protecting against live virus challenge was also seen to be equivalent to that of the H5N1 vaccine. The
protective efficacy of the H1N1 vaccine was also confirmed using a severe combined immunodeficient (SCID) mouse model.
It was demonstrated that mouse and guinea pig immune sera elicited following active H1N1 vaccination resulted in 100%
protection of SCID mice following passive transfer of immune sera and lethal challenge. The immune responses to a whole
virus pandemic H1N1 and a split seasonal H1N1 vaccine were also compared in this study. It was demonstrated that the
whole virus vaccine induced a balanced Th-1 and Th-2 response in mice, whereas the split vaccine induced mainly a Th-2
response and only minimal levels of Th-1 responses. These data supported the initiation of clinical studies with the same
low doses of whole virus vaccine that had previously been demonstrated to be immunogenic in clinical studies with a
whole virus H5N1 vaccine.
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Introduction
In April 2009, an outbreak of influenza in North America was
found to be caused by a new strain of influenza virus [1]. This
swine-origin influenza virus was determined to be a novel strain of
A/Influenza H1N1 serotype which had been derived by reassort-
ment of swine, avian and human influenza viruses. The virus
rapidly spread to a large number of countries and on June 11,
2009 the WHO declared that the infections caused by the new
strain had reached pandemic proportions. As of end of January,
2010, WHO has reported approx. 14700 deaths in more than 209
countries resulting from pandemic influenza H1N1 [2]. However,
given that countries are no longer required to test and report
individual cases, the number of reported cases significantly
understates the real number of cases.
Most confirmed cases of pandemic H1N1 infection have been
characterized by self-limited, uncomplicated febrile respiratory
illness and symptoms similar to those of seasonal influenza.
However a substantial number of hospitalized individuals did not
have underlying health issues, suggesting that the pathogenic
potential of this pandemic H1N1 virus may be different to that of
seasonal influenza virus strains [3].
Immunization provides the best preventive strategy against
influenza virus illness. The current trivalent vaccine is unlikely to
provide significant protection against the novel pandemic H1N1
strain. It has been reported that previous vaccination of children
with trivalent vaccine of the last four seasons i.e. 2005–2006 to
2008–2009, did not elicit a cross-reactive antibody response to the
pandemic H1N1 strain [4]. Thus a monovalent vaccine based on
the novel H1N1 strain will be required to induce protective
immunity. Standard H1N1 vaccine components of the trivalent
seasonal vaccine consist of 15 mg hemagglutinin (HA) of split or
subunit non-adjuvanted preparations. However, it has been
reported that up to 90 mg of a non-adjuvanted subvirion candidate
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protective immune response levels in 58% of subjects after two
immunizations [5]. It has however been reported that 7.5 mgH A
of a whole virus H5N1 vaccine induced seroneutralizing responses
in 76% of subjects after two immunizations [6] and it has also been
reported that whole virus trivalent seasonal influenza vaccines are
more immunogenic than non-adjuvanted subvirion vaccines [7].
Based on these reports, a whole virus H1N1 vaccine was
developed with the expectation that this would facilitate
substantial antigen sparing, which would allow the availability of
larger amounts of vaccine compared to the use of subvirion
technology. The first pre-clinical immunogenicity and animal
protection studies described here suggest that this H1N1 vaccine
will be effective in protecting against pandemic influenza illness in
humans.
Materials and Methods
Ethics Statement
All animal experiments were reviewed by the Institutional
Animal Care and Use Committee and approved by the Austrian
regulatory authorities. All animal experiments were conducted in
accordance with Austrian laws on animal experimentation and
guidelines set out by the Association for Assessment and
Accreditation of Laboratory Animal Care International (AAA-
LAC) and the Office of Laboratory Animal Welfare (OLAW).
Animals were housed according to OLAW and AAALAC
guidelines, in housing facilities accredited by the AAALAC.
Vaccine Strains and Reagents
Influenza viruses (A/California/07/2009 (H1N1; CDC#
2009712112), A/Vietnam/1203/2004 (H5N1; CDC#2004706280)
and A/Brisbane/59/2007 (H1N1; NIBSC 07/346)), hemagglutinin
(HA) antigens (A/California/7/2009 (NIBSC 09/146), A/Brisbane/
59/2007 (NIBSC 08/100) and A/Vietnam/1203/2004 (CBER
#50)), and antisera (A/California/7/2009 (NIBSC 09/152), A/
Brisbane/59/2007 (NIBSC 08/112) and A/Vietnam/1203/2004
(CBER #S-APS1 L2)) were obtained from the Centers for Disease
Control and Prevention (CDC, Atlanta, USA), the National Institute
for Biological Standards and Control (NIBSC, UK), or the Center for
Biologics Evaluation and Research (CBER). Baculovirus-derived
recombinant HA (rHA) antigens were purchased from Protein
Sciences (UK).
Vaccine Production
Viruses amplified in serum protein free Vero cells in 100 L or
6000 L bioreactors were harvested, double-inactivated and
purified as previously described. This involved use of a double
inactivation procedure as established previously for H5N1
vaccines in order to ensure an extremely high margin of safety
for this highly pathogenic virus [8–10]. Hemagglutinin (HA)
antigen content was determined by single radial immunodiffusion
assay [11] for A/Brisbane/59/2007 and A/Vietnam/1203/2004
and by HPLC analysis for A/California/07/2009 vaccines.
Immunization and Challenge of CD1 Mice
Female CD1 mice (6–9 weeks old) were subcutaneously (s.c.)
injected with vaccine or buffer on days 0 and 21. Functional HA-
specific antibody titers were determined via hemagglutination
inhibition (HI) or micro neutralization (MN) assays on days 21 and
42. On day 42, mice were challenged intranasally with 1610
5
TCID50 units of wild-type virus. Mice administered H5N1 virus
were monitored for 14 days post-challenge for disease symptoms
and death. Mice administered H1N1 virus were euthanized 3 days
post-challenge and infectious virus in lung tissue was detected
using a TCID50 assay. The protective dose 50% (PD50) was
determined by survival or undetectable virus titers in the lungs
following challenge with H5N1 or H1N1 virus, respectively. In
addition, 100 ml of the lung tissue samples were applied directly to
Roux flasks (75 cm
2, NUNC, Cat.-No 178905) followed by a
complete medium change 1 hour after inoculation. The cells were
screened for CPE after 6 days of incubation at 37uC to overcome
the cytotoxic effects seen at higher concentrations in the TCID50
assay.
Immunizations of Balb/c Mice for Analysis of Cellular and
Humoral Immunity
Balb/c mice (8–10 weeks old) were injected s.c. either once (on
day 0) or twice (on days 0 and 21) with 3.75 mg of vaccine or
buffer. On day 42, eye bleeds were taken by orbital puncture for
IgG subclass and HI titer determinations. On days 7 and 42,
spleens were obtained from euthanized animals for IFN-c and IL-
4 ELISPOT analyses.
Microneutralization (MN) Assay
Functional H5N1 HA-specific antibody titers were determined
using an MN assay, as previously described [10], and the effective
dose fifty percent (ED50) required to induce neutralizing antibody
titers of $20 was determined.
Hemagglutination Inhibition (HI) Assay
Functional H1N1 HA-specific antibody titers were determined
by HI assay using chicken erythrocytes, and the ED50 required to
induce seroprotection was determined. Sera giving a negative
signal in the first dilution (,1:10) were assigned a nominal HI
score of 1:5. HI titers are expressed as reciprocal of serum dilution.
Animals with a serum HI titer of $40 were considered
seroprotected.
TCID50 Assay (Tissue Culture Infectious Dose 50%)
Serial ten-fold dilutions of virus-containing samples were
inoculated into 96-well microtiter plates seeded with Madin-
Darby canine kidney (MDCK) cells, and incubated for 5–6 days at
37uC. Cytopathic effects in individual wells were determined via
light microscopy.
IFN-c and IL-4 ELISPOT Assay
The frequency of IFN-c- or Interleukin-4 (IL-4)-secreting cells
was analyzed using mouse IFN-c and IL-4 enzyme-linked
immunospot (ELISPOT) kits (Mabtech AB, Nacka, Sweden), as
previously described [10], using vaccine antigen at a concentration
of 0.3 mg HA/ml.
IgG Subclass Determination
ELISA plates were coated overnight at 4uC with either rHA or
polyclonal anti-mouse Fab2 IgG (Sigma). After blocking non-
specific binding and subsequent washing, diluted sera or serial
dilutions of purified murine IgG1, IgG2a or IgG2b (Sigma) were
added to the wells containing rHA or Fab2 IgG, respectively. Plates
were incubated for 1 h at room temperature, washed again, prior to
further incubation for 1 h with IgG subclass-specific peroxidase-
conjugated goat anti-mouse IgG antibodies. Bound IgG subclass
antibodies were detected colorimetrically using TMB substrate.
H1N1 Challenge and Passive Protection of SCID Mice
Female severe combined immunodeficient (SCID) 4–5 week old
mice (strain CB17/Icr-Prkdc
scid/IcrCrl) were intranasally chal-
Pandemic H1N1 Vaccine
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5 TCID50 units of wild-type virus, and
monitored for 30 days for disease symptoms and death. For
passive immunization, 200 ml of either naive mouse, or immunized
mouse or guinea pig sera were injected intraperitoneally at days 0
and 1 prior to intranasal challenge at day 2. Immune sera were
generated in CD1 mice or guinea pigs immunized twice with
3.75 mg H1N1 vaccine at days 0 and 21, and serum pools were
obtained at day 42.
Statistical Analyses
PD50,E D 50 and TCID50 values were calculated using in-house
software based on the one-hit model [12].
Results
1. Dose-Dependent Immunogenicity of H1N1 Vaccine in
Mice
To provide initial guidance with respect to dosing for clinical
trials, groups of ten mice were immunized twice, with a three week
interval and with five-fold dilutions of antigen doses ranging from
3.75 mg to 0.0012 mg HA. Hemagglutination inhibition (HI) titers
were determined in the individual mice and a geometric mean titer
(GMT) was determined for each dosage group, 21 days after the
first and second immunization (Table 1). Seroconversion, as
defined by an HI geometric mean titer $40, was achieved after a
single dose with the 3.75 mg, 0.75 mg and 0.15 mg formulations
(GMT’s of 139, 86 and 53 respectively). These titers had increased
substantially when measured 21 days after booster immunization.
The highest mean GMT (970) was achieved 21 days after booster
immunization with the 3.75 mg formulation. All individual mice
demonstrated an HI titer $40 with as little as 0.75 mg HA antigen
after one immunization and 0.03 mg after two immunizations.
2. Dose Dependent Protection of Mice by H1N1
Candidate Vaccine
To evaluate the ability of the H1N1 vaccine to induce protective
immune responses, a mouse challenge and protection model was
established by intra-nasal challenge of CD1 and Balb/c mice with
virus titers ranging from 10
2 to 10
5 TCID50. No lethality was
observed at any challenge dose although clear symptoms of ruffled
hair and buckled back could be observed within two days after
infection. This was in agreement with a previous report for
infection of Balb/c mice with the novel H1N1 virus [13].
Maximum virus titers could be determined in the lungs of infected
animals three days after challenge with 10
5 TCID50 of H1N1 virus
in the CD-1 mice (data not shown). This model was then utilized
to investigate the protective efficacy of the candidate vaccine. The
out-bred CD-1 strain was also considered to better reflect the
human genetic situation than the inbred Balb/c mouse strain.
Groups of 5 mice were s.c. immunized twice with decreasing doses
of vaccine ranging from 3.75 mg to 0.0012 mg antigen before being
challenged intra-nasally with 10
5 TCID50 of H1N1 A/California/
7/2009, 21 days after the booster immunization. Three days after
challenge, the lungs of immunized and control mice were
harvested and virus titers were determined (see Methods.
Maximum virus titers of 10
5.5 TCID50/ml of resuspended lung
tissue were obtained for control animals after challenge while a
titer less than ,10
1.1 TCID50/ml (level of detection due to toxicity
of lung tissue in tissue culture) was determined to be indicative of
protection.
The data presented in Fig. 1 demonstrate that 100% protection
with respect to undetectable virus titers in lung tissue could be
obtained following immunization with two doses of 3.75 mgH A
antigen whereas 80% protection could be obtained with as little as
0.15 mg.
3. Effective Dose 50% (ED50) and Protective Dose 50%
(PD50) Comparison between Seasonal and Pandemic
H1N1 and H5n1 Vaccines
As no data is available about the efficacy of the present
generation of candidate pandemic vaccines, comparative immu-
nogenicity studies were done with an H5N1 vaccine and an H1N1
component (A/Brisbane/59/2007) of a standard seasonal vaccine,
both of which have been in extensive clinical trials and have been
demonstrated to be highly immunogenic with high levels of
seroconversion and seroprotection in humans [6,14,15]. ED50 and
PD50 determinations were calculated for the three vaccines after
immunization of groups of mice with two doses of serial dilutions
of vaccine antigen as described in Methods. These data (Table 2)
demonstrate that the three vaccines were comparable with respect
to immunogenicity with mean ED50 values of 15 ng, 13 ng and
Table 1. Dose-dependent immunogenicity of H1N1 A/
California/7/2009 candidate vaccine in mice.
A/California/7/2009
Dose/mg HA d21 d42
%SC GMT %SC GMT
3,75 mg 90% 139 100% 970
0,75 mg 100% 86 100% 537
0,15 mg 70% 53 100% 343
0,03 mg 40% 15 100% 243
0,006 mg 10% 7 50% 32
0,0012 mg0 % 5 0 % 5
Buffer 0% 5 0% 5
ED50 57 ng 7 ng
CD1 mice were immunized twice with different doses of the candidate vaccine,
and HI titers were determined 21 days after the first (d21) and 21 days after the
booster immunization (d42) to calculate the percentage of seroconversion
(%SC), geometric mean titers (GMT), and effective dose 50 (ED50) based on an HI
titer of $40.
doi:10.1371/journal.pone.0009349.t001
Figure 1. Protection of mice from lung viremia. Groups of CD1
mice were immunized twice with five-fold serial dilutions of pandemic
H1N1 (H1N1 A/California/7/2009) whole virus vaccine, before being
challenged intranasally with 10
5 TCID50. Lungs were harvested at day
three after challenge, and virus titers determined as described
(Methods). Lack of detection of virus in lungs was considered indicative
of protection.
doi:10.1371/journal.pone.0009349.g001
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H5N1 Vietnam. PD50 values could not be determined for the
seasonal H1N1 Brisbane strain because of the lack of an
appropriate challenge model but comparison of the two pandemic
strain vaccines demonstrated similar levels of protection with
values of 5 ng and 8 ng being obtained for the H1N1 and H5N1
vaccines respectively.
4. T helper Cell and IgG Subclass Responses in Mice
The type of cellular immune response induced by the pandemic
H1N1/California vaccine was characterized and compared with
that produced by the pandemic H5N1/Vietnam and seasonal
H1N1/Brisbane vaccines using inbred Balb/c mice. After each
immunization, homologous and heterologous T-helper cell respons-
es were evaluated by IFN-g and IL-4 ELISPOT analyses as
described in Methods. Spleen cells were collected 7 days after the
first and 21 days after the second immunization (day 42) and
stimulated with seasonal or pandemic influenza virus antigens. The
Th-1 (IFN-g) responses were found to be highest on day 7 (Fig. 2A),
while Th-2 (IL-4) responses were higher on day 42 (Fig. 2B). In the
case oftheH1N1 California immunizedmice,thehighestTh-1type
responses were obtained following stimulation with the homologous
antigen, although substantial cross-reactive responses were also seen
after stimulation with H5N1 Vietnam and to a lesser extent
following H1N1 Brisbane stimulation. Numbers of IFN-g secreting
cells specific for the homologous antigen were comparable in mice
immunized with pandemic whole viral vaccines, but lower for the
mice immunized with the split influenza vaccine.
The Th-2 responses to H1N1 California showed a similar
picture with the highest IL-4 response directed against the
homologous antigen. Substantial cross-reactive responses were
Table 2. ED50 and PD50 comparison between seasonal and
pandemic H1N1, and pandemic H5N1 vaccines.
Vaccine ED50 PD50
mean SD N mean SD N
H1N1 A/Brisbane/59/2007 15 ng
1 4 2 n.a. n.a. n.a.
H1N1 A/California/7/2009 13 ng
1 11.4 3 5 ng
3 3.6 3
H5N1 A/Vietnam/1203/
2004
34 ng
2 21 6 8 ng
4 69
n.a. not applicable (no challenge model available).
1 based on an HI titer of $40.
2 based on a MN titer of $20.
3 based on the titer of infectious virus in the lungs of mice 3 days after
challenge.
4 based on survival of mice 14 days after challenge.
Groups of mice were immunized twice with serial dilutions of antigen doses up
to 5 mg of seasonal H1N1 (H1N1 A/Brisbane/59/2007), pandemic H1N1 (H1N1
A/California/7/2009) and pandemic H5N1 (H5N1 A/Vietnam/1203/2004)
vaccines. The minimum antigen dose that resulted in seroconversion (ED50)o r
protection against challenge (PD50) of 50% of immunized animals was
determined, and is given as mean with standard deviation (SD) and number of
study replicates tested (N).
doi:10.1371/journal.pone.0009349.t002
Figure 2. Th-1 and Th-2 cytokine responses in mice immunized with seasonal and pandemic H1N1, and pandemic H5N1 vaccines.
Balb/c mice were immunized with pandemic H1N1 (H1N1 A/California/7/2009), seasonal H1N1 (H1N1 A/Brisbane/59/2007), and pandemic H5N1
(H5N1 A/Vietnam/1203/2004) vaccines. Spleen cells were collected 7 days after the first, or 21 days after the booster immunization (i.e. 42 days after
the first), and stimulated with various seasonal or pandemic influenza virus antigens, before determination of cells responding by secretion of either
IFN-g or IL-4 by an ELISPOT assay. Anti-HA IgG subclass responses were analyzed by ELISA using sera collected on day 42.
doi:10.1371/journal.pone.0009349.g002
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and split H1N1 Brisbane. Again, the homologous Th-2 responses
of the two whole virus pandemic vaccines were comparable, while
that to seasonal H1N1 Brisbane, in this case, was slightly higher.
Overall, the whole viral vaccines induced similar numbers of IFN-
g and IL-4 secreting cells on day 7, indicating an initial mixed Th-
1/Th-2 response, which shifted after the booster immunization to
a predominant Th-2 response. In contrast, there was little or no
Th-1 response induced by the split H1N1 Brisbane vaccine on
Day 7, and thus a Th-2 response bias was observed already on day
7, after the first immunization.
To further substantiate the difference between the type of
cellular responses elicited by the whole viral pandemic H1N1
California and H5N1 Vietnam vaccines in comparison to the split
seasonal H1N1 Brisbane vaccine, anti-HA IgG subclass responses
were analyzed by ELISA as described in Methods, using sera
collected on day 42. While anti-HA IgG1 subclass antibody
responses, characteristic of a Th-2 type response, were dominant
for all 3 vaccines (Fig. 2C), substantial IgG2a and IgG2b subclass
antibody responses, characteristic of Th-1 responses, were only
detected in mice immunized with the whole viral pandemic
vaccines. This indicates that whole virus vaccines are capable of
inducing both Th-1 and Th-2 responses, whereas the split vaccine
produces strong Th-2 responses with only minimum levels of Th-1
type T cell or Th-1 driven IgG subclass responses.
5. Protection of SCID Mice by Passive Transfer of Immune
Serum
The results of the immunizationand challenge studies reported in
Fig. 1 demonstrated that the H1N1 vaccine was capable of
preventing virus replication in the lungs after challenge with high
titer H1N1 virus. These studies were further extended to
demonstrate the protective efficacy of the vaccine using a SCID
mouse model which was more sensitive to H1N1 infection. Intra-
nasal (i.n.) challenge of SCID mice with H1N1 resulted in infection
with a dose dependent lethality, unlike the situation with Balb/c or
CD 1 mice where no lethality was observed. Lethal infection of
SCID mice was achieved after i.n. infection with a LD50 of 3.860.3
log10 TCID50 (mean 6 SD, N=2).After infectionwith10
5 TCID50
all mice died, with a mean survival time of 18 days. This sensitive
model was therefore utilized to determine the protective efficacy of
vaccination using a passive transfer model. Following immunization
of mice and guinea pigs with the H1N1 vaccine, sera pools were
prepared and H1N1 specific HI titers were determined. An HI titer
of 640 was measured in both mouse and guinea pig preparations.
Groups of 6 SCID mice were twice injected i.p. with 200 mlo f
immune sera from both pools or with naı ¨ve mouse serum, 24 hours
apart. One day after the second passive transfer these groups and a
control non-treated group of mice were i.n. challenged with 10
5
TCID50 H1N1 in a 20 ml volume.
The data presented in Fig. 3 demonstrates that passive transfer of
serum from either mice or guinea-pigs immunized with the A/
California/07/2009 H1N1 vaccine resulted in complete protection
with no lethalities over a 30 day observation period. In contrast all
mice which received naı ¨ve serum or were in a control non-treated
group died between 13 and 25 days. Clinical monitoring for disease
symptoms (ruffled fur, hunched back, exhaustion) was also carried
out over a period of 30 days. While the control mice demonstrated
symptoms by day 10 following challenge, no clinical symptoms were
observed in the mice receiving anti-H1N1 sera.
At the end of the experiment at day 30, lungs of the surviving
animals were collected. All these animals were symptom-free at
this stage but all had virus titers detectable in the lungs. Mean
titers of 10
4.2 and 10
4.0 TCID50 were measured in mice treated
with mouse or guinea-pig antisera respectively, whereas in non-
treated controls, examined at first onset of symptoms, the titers
were 2 to 3 logs higher.
Discussion
This study was designed to assess the immunogenicity and
protective efficacy of a candidate vaccine against the pandemic A/
California/07/2009 pandemic H1N1 virus in animal models,
prior to initiation of human clinical studies. It had been previously
reported that a candidate pandemic H5N1 vaccine produced by
an identical process was highly immunogenic and protective in
mouse models [9]. These studies were subsequently demonstrated
to be highly predictive of the immunogenicity demonstrated in
human trials, particularly with respect to immunogenicity at low
doses and the lack of immune enhancement by use of an alum
based adjuvant [7].
As such it was considered that similar studies would be valuable
in assessing the optimal dosing for clinical trials with the H1N1
candidate vaccine. In addition although surrogate serological
markers for seasonal influenza vaccine have been established [16],
no clear cut correlate for protection has been established for
potential pandemic vaccines such as H5N1 or novel H1N1 strain
vaccines. Thus data obtained from animal protection studies could
be of value in combination with data obtained from human dose-
finding and observational efficacy studies following vaccine use in
a pandemic situation such as presently exists for the novel H1N1
virus.
The data illustrated in Table 1 was encouraging in that
immunization with as little as 30 ng HA antigen resulted in a mean
GMT of 243 as measured in the HI assay after two immuniza-
tions. Following a single dose immunization regimen as little as
0.15 mg still resulted in a mean HI titer response above the
accepted 1:40 threshold for seroprotection in humans for seasonal
influenza vaccines. These data with a non-adjuvanted whole virus
H1N1 vaccine were similar or superior to those obtained for a
MF59 adjuvanted subunit H1N1 vaccine in mouse studies, where
0.5 mg induced an average HI titer of 63 after one immunization.
In contrast the non-adjuvanted split vaccine used in those studies
resulted in substantially lower HI titer responses [17]. The
immunogenicity of the MF59 adjuvanted vaccine has been
subsequently confirmed in human studies with a 7.5 mg dosage
resulting in 80% seroprotection after a single immunization [18].
The immunogenicity described in Table 1 was also supported
by the data obtained in challenge studies, with no virus being
Figure 3. H1N1 challenge and passive protection of SCID mice.
SCID mice were challenged with 10
5 TCID50 pandemic H1N1 (H1N1 A/
California/7/2009) by intranasal instillation, and survival monitored for
30 days. For passive protection, 200 ml immune mouse or guinea pig
(GP) sera, or naı ¨ve mouse serum, were intraperitoneally administered to
mice both at days one and two prior to virus challenge.
doi:10.1371/journal.pone.0009349.g003
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with two doses of 3.75 mg HA antigen and 80% protection being
obtained with as little as 0.15 mg.
The probability of pandemic H1N1 vaccine efficacy in humans
was further analyzed by comparison with the immunogenicity of a
seasonal monovalent H1N1 vaccine (A/Brisbane/59/2007) which
was demonstrated to be highly immunogenic as a component of a
trivalent split seasonal vaccine in multiple human trials [14] and
with a whole virus H5N1 vaccine which was also highly
immunogenic in human trials [6,15] and highly protective in
pre-clinical lethal mouse challenge studies [10]. The data
presented in Table 2 demonstrated that the three vaccines were
comparable with respect to immunogenicity with mean ED50
values of 15 ng, 13 ng and 34 ng being obtained for the seasonal
H1N1 Brisbane, the H1N1 California and the H5N1 Vietnam
vaccines respectively. The H1N1 California and H5N1 vaccines
were also demonstrated to be highly comparable with respect to
protective efficacy with PD50 values of 5 ng and 8 ng being
obtained for the H1N1 and H5N1 vaccines respectively (Table 2).
The ability of the H1N1 vaccine to prevent virus replication in
the lungs of mice may be a predictive marker for disease
prevention in humans. However, the inability of the virus to
induce lethality in the immune competent mouse model prevented
a clear cut assessment of efficacy. Other standard influenza animal
models such as the ferret also do not consistently display clear
clinical signs of infection, and is also not a lethal model for H1N1
California [13,19,20]. In contrast, the SCID mouse was
susceptible to lethal infection but because of its intrinsic immune
deficient nature could not be utilized as a model for active
immunization studies. This model was therefore adapted to
indirectly measure the efficacy of the vaccine in passive transfer
studies. The data presented in Fig. 3 confirm the protective
potential of this vaccine in that immune sera generated by active
immunization of mice and guinea-pigs resulted in 100%
protection of susceptible SCID mice following passive transfer
whereas 100% of control mice succumbed to lethal infection
following challenge with 10
5 TCID50 of infectious virus.
In this study monitoring was discontinued at day 30 i.e. 5 days
after the last death in the control group. All surviving animals were
symptom-free at this stage but following sacrifice it could be
demonstrated that a significant virus titer was present in the lungs,
although the virus load was substantially reduced compared to that
detected in control, non-treated animals. This data confirms
reports that it is difficult to obtain full virus clearance from the
lungs of SCID mice. It has been reported that only high
concentrations of anti-HA specific cocktails of mouse monoclonal
antibodies transferred repeatedly resulted in full virus clearance in
immune deficient mice in an influenza treatment model [21,22].
As such it is possible that disease and death may have occurred in
the healthy SCID mice at a later stage following decline in titers of
passively transferred antibody. However, a recent study with Ebola
virus showed that passive transfer of specific antibodies protects
immune-deficient mice against lethal Ebola virus infection without
complete inhibition of viral replication [23].
The superior immunogenicity of non-adjuvanted whole virus
pandemic H5N1 vaccines compared to non-adjuvanted split virus
vaccines has been demonstrated in clinical studies [5,6]. In this
study we compared the Th-1 and Th-2 responses to immunization
with non-adjuvanted, whole virus pandemic H1N1 and H5N1
vaccines to a split virus H1N1 seasonal vaccine in Balb/c mice.
The data presented in Fig. 2 demonstrate that the whole virus
pandemic H1N1 and H5N1 vaccines are capable of inducing both
Th-1 and Th-2 responses in mice, whereas the seasonal split
H1N1 induced only minimal levels of Th-1 T-cell or Th-1 driven
IgG subclass responses. This differentiated response may at least
partially explain the superior immunogenicity of whole virus
pandemic influenza vaccines compared to non-adjuvanted sub-
virion vaccines
The data reported here indicate that the whole virus pandemic
H1N1 vaccine is immunogenic at low doses and protective in both
active and passive transfer challenge studies. These data supported
the decision to initiate clinical studies with this whole virus non-
adjuvanted vaccine at low doses i.e. 7.5 mg and 3.75 mg despite the
fact that non-adjuvanted split virus H5N1 vaccines have been
poorly immunogenic at dosages up to 90 mg. Preliminary data
from H1N1 clinical studies indicate that both the 3.75 mg and
7.5 mg non-adjuvanted formulation induced high levels of
seroprotective responses (HI titer $1:40) in human studies.
In addition, multiple clinical studies have recently been
published, reporting that a variety of adjuvanted and non-
adjuvanted split virion vaccines can also induce high levels of
seroprotective responses [18,24–32]. It will be highly interesting to
compare field efficacy data (when available) for all of these
vaccines with serological responses in human trials and immuno-
genicity and protection data in animal models as reported here.
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